Lecture 16 - Tumor Immunology and Targeted Therapeutics

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/42

encourage image

There's no tags or description

Looks like no tags are added yet.

43 Terms

1
New cards

Tumor Immunity Cycle

Tumor antigens are released

APC activation

T-cell Priming

T-cell trafficking

Tumor Infiltration

Tumor recognition

Tumor Killing


Immunotherapies can impact each one of these steps

2
New cards

IFN Gamma Normal Actions

Activates macrophages so they can kill microbes

Increases MHC I and MHC II expression to help APCs present antigens to T-cells

Promotes Th1 response

Supports antitumor activity by helping immune cells recognize and attack tumor cells

3
New cards

TGF-Beta Normal Actions

Suppresses immune responses and regulates tissues

Suppresses T cell activity limiting excessive immune response

Promotes regulatory T-cell development preventing autoimmunity

Inhibits certain immune cell functions, reducing inflammation

Promotes tissue repair and fibrosis, depending on the tissue and context

4
New cards

What is required for tumor elimintation

Antigen recognition

T-cell activation

Tumor infiltration

Tumor killing


Tumors can escape by disrupting one or more of these steps

5
New cards

Hot Tumors

Characterized by High CD8 T cell infiltration, High IFN-gamma, Often PD-L1 positive.

6
New cards

Examples of Hot tumors

Melanoma

Hodkin Lymphoma

MSI-high tumors

7
New cards

Cold Tumors

Characterized by few T cells, poor antigenicity, little inflammation.

8
New cards

Examples of cold tumors

Pancreatic cancer

Some prostate cancers

9
New cards

Immune excluded characteristics

T cells are present but the T cells can not enter the tumor

Often associated with TGF-Beta, stromal barriers, and VEGF

10
New cards
11
New cards

Tumor Infiltrating Lymphocytes

In a hot Tumor there are many CD8 cells

In a cold tumor there are few CD8 cells

12
New cards

Likely strategy to combat the different tumor phenotypes

Hot: PD-1 Inhibitor

Cold: Recruitment strategy

Excluded: TME-targeted therapy

13
New cards

What are the 3 major tumor escape mechanisms

Hide from immune recognition

Suppress T-Cell activation

Build an immunosuppressive microenvironment

14
New cards

How do tumors hide from immune recognition

Antigen loss, MHC-1 loss, Defective antigen presentation


Makes it so the T cells cannot recognize the tumor

15
New cards

How do tumors Suppress T-cell activation

They exploit CTLA-4s checkpoint inhibition of T-cells

(CTLA4 (receptor) inhibits CD80 from binding to CD28 which prevents co-stimulation)

They also exploit the PD-1/PD-L1 Checkpoint pathway

(Binding PD to PD-L1 inhibits T cell function)

16
New cards

Consequences of PD-L1 Activation

Reduced Cytokine production

Reduced cytotoxicity

T-cell exhaustion

17
New cards

PD-1 Checkpoint inhibitors

Restore Effector Function and Cytotoxic activity

18
New cards

CAR T Cell Therapy

Chimeric Antigen Receptor T Cell Therapy

Alters the genes in a person’s T cells to help attack cancer. T cells can be taken from patient’s blood and genetically changes in the ab to have a chimeric antigen receptor on its outer surface. These receptors help T cells attach to a specific cancer antigen. The CAR T cells are then returned to patient’s blood.

19
New cards

Kind of Checkpoint inhibitors

PD-1 Inhibitors (Pembrolizumab, Nivolumab)

PD-L1 Inhibitors (Atezolizumab, Durvalumab)

CTLA-4 Inhibitors (Ipilimumab)

20
New cards

Examples of Tumor Suppressive Soluble Mediators

TGF-B

IL-10

Adenosine

VEGF

21
New cards

Emerging tumor therapeutics

Other checkpoints like LAG-3, TIGIT, TIM-3

Microenvironment modifiers

Bispecific antibodies

22
New cards

Major Suppressive Components of Tumor Environment

Tregs

MDSCs

M2 Macrophages

23
New cards

How do tumors form immunosuppressive environments

Heterogeneity of constitution

Lack of Tumor Antigen

Defect of Antigen presenting

Impairment of T-cell infiltration

Activation of immunosuppressive metabolism

24
New cards

Heterogeneity of constitution

Tumor cells are genetically and biologically diverse. Some tumor cells may be less recognizable to the immune system or more resistant to immune attack

25
New cards

Lack of antigen tumor

Tumor cells may not express enough recognizable antigens, or they may lose antigens making them harder for T cells to identify

26
New cards

Defects of antigen presenting

Tumor antigens may not be processed or presented effectively, limiting T-cell recognition and activation

27
New cards

Impairment of T-cell infiltration

T cells cannot efficiently enter or move through the tumor tissue to reach cancer cells

28
New cards

Activation of immunosuppressive signaling pathways

Tumors activate inhibitory mechanisms such as PD-1/PD-L1 signaling and can use cytokines such as TGF-B to suppress immune responses

29
New cards

Enhancement of immunosuppressive metabolism

Tumors alter nutrient availability and produce metabolites that impair T-cell function.

30
New cards

Cytokines modulating therapies

Enhance immune activation and expansion

IL-2 based therapies

IFN based approaches

Engineered cytokines

31
New cards

Emerging Biologics

TGF-Beta inhibitors

CSF1R inhibitors

Adenosine pathway inhibitors

Bispecific antibodies

32
New cards

Combination Immunotherapy

CTLA-4 blockade + PD-1 blockade. Targets both T-cell priming and T-cell activation. Tumors frequently employ multiple escape mechanisms simultaneously, need to administer multiple drugs to target the different pathways.

33
New cards

Kinds of combination therapy

Simultaneous attack - using two or more drugs at the same time to hit different pathways

Sequential attack - using drugs in a specific order one after another to overcome resistance.

34
New cards

Acquired Resistance

Sometimes tumors relapse after immunotherapy.

35
New cards

Potential mechanisms of acquired resistance

Antigen loss

MHC downregulation

Alternative checkpoints (LAG-3, TIGIT)

Immunosuppressive microenvironment adaptation

36
New cards

What makes a good Biomarkers

It should indicate if an immune response is present, why might block it, and if that block can be reversed

37
New cards

Interpreting high IFN gamma

there is an existing antitumor immune response

38
New cards

Interpreting CXCL9/CXCL10

Active T-cell recruitment is occurring

39
New cards

Interpreting high TGF-B

Immune exclusion is occurring

40
New cards

Interpreting high IL-10

There is a suppressive immunoenvironment

41
New cards

What can biomarkers be used for

Screening, prognosis, diagnosis, staging, risk assessment, stratification, monitoring, therapy planning

42
New cards

Why do biomarkers sometimes fail

They can help inform decisions but rarely determine them completely.

PD-L1 expression is dynamic

Different assays produce different scores

Tumors are heterogneous

High PD-l1 does not guarantee a response and low PD-L1 does not guarantee failure

43
New cards

The immunology decision Tree

  1. Is there an immune response

  2. What is preventing tumor elimination

  3. Which pathway can be targeted

  4. Which biomarker supports that choice

  5. Select mechanism-based therapy